NASDAQ: CCAPCrescent Capital Bdc Inc Stock
$11.18+0.25 (+2.29%)
Updated Jul 28, 2026
CCAP Price
$11.18
Fair Value Price
N/A
Market Cap
$411.94M
52 Week Low
$10.64
52 Week High
$16.04
P/E
27.27x
P/B
0.61x
P/S
2.75x
PEG
0.33x
Dividend Yield
15.03%
Revenue
$163.07M
Earnings
$15.09M
Gross Margin
45.5%
Operating Margin
10.32%
Profit Margin
9.3%
Debt to Equity
1.4
Operating Cash Flow
$66M
Beta
0.51
Next Earnings
Aug 10, 2026
Ex-Dividend
Aug 31, 2026
Next Dividend
Sep 15, 2026
CCAP Overview
Crescent Capital BDC, Inc. functions as a Business Development Company (BDC), managing a fund dedicated to private equity, leveraged buyouts, and providing loan capital. The firm's strategy centers on making direct investments, with a specific focus on the middle market segment. Its investment mandate is exclusively for opportunities within the United States.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CCAP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Asset Management
Industry Rating
D
CCAP
Ranked#64 of 79
Ranked#64 of 79
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $82.50 | A | |
| $100.47 | B | |
| $19.74 | B |
Be the first to know about important CCAP news, forecast changes, insider trades & much more!
CCAP News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CCAP scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CCAP ($11.18) is trading below its intrinsic value of $12.78, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CCAP is poor value based on its earnings relative to its share price (27.27x), compared to the US market average (14.6x)
P/E vs Market Valuation
CCAP is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CCAP due diligence checks available for Premium users.
Valuation
CCAP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
27.27x
Industry
33.6x
Market
14.6x
CCAP is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CCAP is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CCAP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.61x
Industry
2.82x
CCAP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CCAP price to earnings growth (PEG)
For valuing profitable companies with growth potential
CCAP is good value based... subscribe to Premium to read more.
PEG Value Valuation
CCAP's financial health
Profit margin
Revenue
$37.9M
Net Income
-$15.5M
Profit Margin
-40.9%
CCAP's Earnings (EBIT) of $16.83M... subscribe to Premium to read more.
Interest Coverage Financials
CCAP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$943.6M
Debt to equity
1.4
CCAP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CCAP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.8M
Investing
$0.0
Financing
$18.8M
CCAP's operating cash flow ($66.05M)... subscribe to Premium to read more.
Debt Coverage Financials
CCAP vs Asset Management Stocks
Crescent Capital Bdc Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.